Unlock instant, AI-driven research and patent intelligence for your innovation.

Anti-rabies-virus combination molecule 2E1

A technology that combines molecules and rabies virus, applied in the fields of biotechnology and immunology, and can solve problems such as limited application

Active Publication Date: 2013-10-30
CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI
View PDF3 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

In 1986, the first murine monoclonal antibody for the treatment of rejection in organ transplantation—murmonab CD3 (murmonab CD3, hoclone OKT3) was approved by the US FDA for marketing, but because it can produce human anti-mouse antibodies in humans ( HAMA) reaction, which limits the application

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-rabies-virus combination molecule 2E1
  • Anti-rabies-virus combination molecule 2E1
  • Anti-rabies-virus combination molecule 2E1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0093] Embodiment 1, the acquisition of peripheral blood mononuclear cells (PBMC)

[0094] Peripheral blood was drawn from volunteers who had been injected with rabies virus vaccine, and conventional Ficoll-Paque (manufacturer: (CEDARLANE) company) density gradient centrifugation, to obtain 10 7 Above peripheral blood mononuclear cells (PBMC).

[0095] Ficoll separation method:

[0096] (1) Collect 10ml of whole blood in a 50ml centrifuge tube (pre-containing 1ml of 4% (w / v) sodium citrate), invert and mix 8-10 times (the final concentration of sodium citrate is 0.4%);

[0097] (2) Add an equal volume of RPMI 1640 (containing sodium citrate), and mix well;

[0098] (3) Use a 15ml transparent centrifuge tube to spread 3ml of lymphocyte separation medium, and carefully add 6ml of blood sample on it. Form the separation interface (or 4ml separation solution plus 8ml blood sample) Tube B: 500μl Opti-MEM+20μl Lipofectamine Reagent;

[0099] (4) Centrifuge at room temperature ...

Embodiment 2

[0103] Example 2, G protein-specific memory B cell sorting

[0104] Using FITC-CD19 / APC-IgG / Cy3-RV-G as a marker, the specific B cells were obtained by flow cytometry to a 96-well RT-PCR plate, with one cell per well to obtain G protein-specific memory B cells.

[0105] 1) Rabies virus envelope protein G protein (RV-G) (G protein of Rabies virus strain SRV9, GenBank: AF499686.2, position 3317-4894 in the complete genome sequence) was expressed by mammalian cell CHO expression system (purchase From Invitrogen Company, prepared according to the experimental instructions);

[0106] 2) Protein G was labeled with biotin: No-Weigh Sulfo-NHS-LC-Biotin (purchased from PIERCE) 10 mM reagent; the other two markers FITC-CD19A and APC-IgG were purchased from BD Bioscience;

[0107] 3) Labeling of sorted cells: PBMC cells were divided into groups, experimental group + control group, markers were added according to the number of cells, stained in the dark, and labeled, resuspended in PBS, ...

Embodiment 3

[0110] Embodiment 3, antibody gene

[0111] For the antibody secreted by B cell 2E1, the experiment was carried out according to the method reported in the literature (Journal of Immunological Methods 329 (2008) 112-124), that is, the antibody heavy and light chain variable region genes were obtained by RT and Nested-PCR methods, with a molecular weight of about 400bp , β-actin as an internal reference (343bp), the electrophoretic patterns of β-actin, heavy chain gene and light chain gene are shown in figure 2 , image 3 with Figure 4 . The variable region of the heavy and light chain gene of the antibody derived from the same B cell was connected to the pGEMT vector (purchased from Invitrogen), and the antibody gene was sequenced and verified. The obtained 2E1 fully human antibody gene sequence is as follows:

[0112] 2E1 heavy chain variable region gene sequence (SEQ ID NO: 1) (5'→3'):

[0113] CAGGTGCAGCTGCAGGAGTCGGGCCCAGGACTGGTGA AGCCTTCGGAGACCCTGTCCCTCACCTGCACTGTCT...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an anti-rabies-virus combination molecule 2E1. The combination molecule provided by the invention can combine rabies virus with native conformation; and compared with some animal-derived combination molecules, the combination molecule provided by the invention has greatly reduced immunogenicity and favorable affinity. The invention has the advantages of favorable curative effect and low side effect.

Description

technical field [0001] The invention belongs to the fields of biotechnology and immunology; more specifically, the invention relates to an anti-rabies virus binding molecule. Background technique [0002] Rabies is a viral zoonotic disease that can be transmitted between humans and animals. Most human rabies infections begin with a bite or scratch from an RV-infected animal, through which the virus enters the body through the animal's saliva. The clinical manifestations of human rabies can be divided into four stages, the incubation period (1-3 months on average, without any symptoms), the prodromal period (the infected person begins to have general discomfort, fever, fatigue, restlessness and other symptoms), the excitement period (the whole body Convulsions, hallucinations, fear of water, light, and wind), coma (deep coma, and finally suffocation or exhaustion due to throat spasm). Rabies is almost 100% fatal in unvaccinated animals or humans (see A Human Monoclonal Anti...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K16/10C12N15/13C12N15/63C12N1/15C12N1/19C12N1/21C12N5/10G01N33/577A61K39/42A61P31/14
Inventor 孙兵王凌凌边超陈爱中凌志洋贾茜魏敬双
Owner CENT FOR EXCELLENCE IN MOLECULAR CELL SCI CHINESE ACAD OF SCI